Antitumor activities of a novel indolin-2-ketone compound, Z24: More potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells

European Journal of Pharmacology

Volumn 502, Issue 1-2, 2004, Pages 1-10

  Wang, Li Li ^a   Li, Jin Jun ^b   Zheng, Zhi Bing ^a   Liu, Hong Ying ^a   Du, Gang Jun ^a   Li, Song ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Antitumor; Bcl 2; bFGF; VEGF; Z24

Indexed keywords

[(1H PYRROL 2 YL)METHYLIDENE] 1 (1 PIPERIDINYLMETHYL) 1,3 2H INDOL 2 ONE; BASIC FIBROBLAST GROWTH FACTOR; KETONE DERIVATIVE; PROTEIN BCL 2; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENESIS; CARCINOMA CELL; CELL PROLIFERATION; CELL STRAIN; CELL VIABILITY; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 4944241352     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.048     Document Type: Article

References (29)

1. A. Bikfalvi, and R. Bicknell Recent advanced in angiogenesis, anti-angiogenesis and vascular targeting Trends Pharmacol. Sci. 23 2002 576 582
2. J.K. Buolamwini Novel anticancer drug discovery Curr. Opin. Chem. Biol. 3 1999 500 509
3. A. Degterev, A. Lugovskoy, M. Cardone, B. Mulley, G. Wagner, T. Mitchison, and J. Yuan Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL Nat. Cell Biol. 3 2001 173 182
4. J.S. de Jong, P.J. van Diest, P. van der Valk, and J.P. Baak Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer: II. Correlations with proliferation and angiogenesis J. Pathol. 184 1998 53 57
5. I.J. Enyedy, Y. Ling, K. Nacro, Y. Tomita, X. Wu, Y. Cao, R. Guo, B. Li, X. Zhu, Y. Huang, Y.Q. Long, P.P. Roller, D. Yang, and S. Wang Discovery of small molecule inhibitors of bcl-2 through structure based computer screening J. Med. Chem. 44 2001 4313 4324
6. J. Folkman Anti-angiogenesis: new concept for therapy of solid tumors Ann. Surg. 175 1972 409 416
7. T.A. Fong, L.K. Shawver, L. Sun, C. Tang, H. App, T.J. Powell, Y.H. Kim, R. Schreck, X. Wang, W. Risau, A. Ullrich, K.P. Hirth, and G. McMahon SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth multiple tumor types Cancer Res. 59 1999 99 106
8. E. Genersch, M. Ferletta, I. Virtanen, H. Haller, and P. Ekblom Integrin alphavbeta3 binding to human alpha5-laminins facilitates FGF-2- and VEGF-induced proliferation of human ECV-304 carcinoma cells Eur. J. Cell Biol. 82 2003 105 117
9. H.P. Gerber Anti-angiogenesis: biology is the foundation for therapy DDT 8 2003 344 346
10. H.P. Gerber, V. Dixit, and N. Ferrara Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells J. Biol. Chem. 273 1998 13313 13316
11. D.S. Grant, K. Tashiro, B. Segui-Real, Y. Yamada, G.R. Martin, and H.K. Kleinman Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro Cell 58 1989 933 943
12. J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, G.D. Yancopoulos, and S.J. Wiegand Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998
13. A. Iervolino, D. Trisciuoglio, D. Ribatti, A. Candiloro, A. Biroccio, G. Zupi, and D. Del Bufalo Bcl-2 over-expression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity FASEB J. 16 2002 1453 1455
14. Y. Kubora, H.K. Kleinman, G.R. Martin, and T.J. Lawley Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures J. Cell Biol. 107 1988 1589 1598
15. J.J. Li, C. Ge, H.X. Zhu, D.F. Wan, and J.R. Gu Establishment of high-throughput technical platform for tumor angiogenesis research Tumor (in Chinese) 21 2001 435 440
16. Li, S., Zheng, Z.B., Shen, P.F., L, C., Zhang, X.M., 2002.08.28. Indole derivatives and their use of anti-tumor [P]. China Patet. 1365972A.
17. H.Y. Lu, C. Lin, S. Li, Z.B. Zheng, X.Y. Zhang, L.S. Zhang, G.Z. Xu, S.X. Guo, M. Fu, X. Liang, and M. Wu Antitumor activity of an indolin-2-ketone compound Z24 in vivo and its anti-angiogenesis activity Chin. J. Pharmacol. Toxicol. 17 2003 401 407
18. S. Madhusudan, and A.L. Harris Drug inhibition of angiogenesis Curr. Opin. Pharmacol. 2 2002 403 414
19. N.M. Mazure, E.Y. Chen, K.R. Laderoute, and A.J. Giaccia Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element Blood 90 1997 3322 3331
20. D.B. Mendel, A.D. Laird, B.D. Smolich, R.A. Blake, C. Liang, A.L. Hannah, R.M. Shaheen, L.M. Ellis, S. Weitman, L.K. Shawver, and J.M. Cherrington Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent Anti-Cancer Drug Des. 15 2000 29 41
21. J.E. Nör, J. Christensen, J. Liu, M. Peters, D.J. Mooney, R.M. Strieter, and P.J. Polverini Up-regulation of bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth Cancer Res. 61 2001 2183 2188
22. J.C. Reed Bcl-2 family proteins: strategies for overcoming chemo-resistance in cancer Adv. Pharm. 41 1997 501 533
23. A. Ricca, A. Biroccio, D.D. Bufalo, A.R. Mackay, A. Santoni, and M. Cippitelli Bcl-2 over-expression enhances NF-kappa B activity and induces MMP-9 transcription in human MCF-7(ADR) breast-cancer cells Int. J. Cancer 86 2000 188 196
24. N.O. Schmidt, M. Westphal, C. Hagel, S. Ergun, D. Stavrou, E.M. Rosen, and K. Lamszus Levels of vascular endothelial growth factor, hepatocyte factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis Int. J. Cancer 84 1999 10 18
25. G. Seghezzi, S. Patel, C.J. Ren, A. Gualandris, G. Pintucci, E.S. Robbins, R.L. Shapiro, A.C. Galloway, D.B. Rifkin, and P. Mignatti Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis J. Cell Biol. 141 1998 1659 1673
26. S.P. Tzung, K.M. Kim, G. Basanez, C.D. Giedt, J. Simon, J. Zimmerberg, K.Y.J. Zhang, and D.M. Hockenbery Antimycin A mimics a cell-death-inducing inducing Bcl-2 homology domain3 Nat. Cell Biol. 3 2001 183 191
27. J.L. Wang, D. Liu, Z.J. Zhang, S. Shan, X. Han, S.M. Srinivasula, C.M. Corce, E.S. Alnemri, and Z. Huang Structure-based discovery of a novel organic compound that binds to Bcl-2 protein and induces apoptosis of tumor cells Proc. Natl. Acad. Sci. U. S. A. 97 2000 7124 7129
28. A. Ziegler, G.H. Luedke, D. Fabbro, K.H. Altmann, R.A. Stahel, and U. Zangemeister-Wittke Induction of apoptosis in small cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence J. Natl. Cancer Inst. 89 1997 1027 1036
29. J.Y. Zhang Apoptosis-based anticancer drugs Nat. Rev., Drug Discov. 1 2002 101 102